Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

The HK2 Dependent "Warburg Effect" and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate.

Lis P, Dyląg M, Niedźwiecka K, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Molecules. 2016 Dec 15;21(12). pii: E1730. Review.

2.

Glutathione may have implications in the design of 3-bromopyruvate treatment protocols for both fungal and algal infections as well as multiple myeloma.

Niedźwiecka K, Dyląg M, Augustyniak D, Majkowska-Skrobek G, Cal-Bąkowska M, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Oncotarget. 2016 Oct 4;7(40):65614-65626. doi: 10.18632/oncotarget.11592.

3.

Screening the yeast genome for energetic metabolism pathways involved in a phenotypic response to the anti-cancer agent 3-bromopyruvate.

Lis P, Jurkiewicz P, Cal-Bąkowska M, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Oncotarget. 2016 Mar 1;7(9):10153-73. doi: 10.18632/oncotarget.7174.

4.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Review.

5.

Dysregulated metabolism contributes to oncogenesis.

Hirschey MD, DeBerardinis RJ, Diehl AME, Drew JE, Frezza C, Green MF, Jones LW, Ko YH, Le A, Lea MA, Locasale JW, Longo VD, Lyssiotis CA, McDonnell E, Mehrmohamadi M, Michelotti G, Muralidhar V, Murphy MP, Pedersen PL, Poore B, Raffaghello L, Rathmell JC, Sivanand S, Vander Heiden MG, Wellen KE; Target Validation Team.

Semin Cancer Biol. 2015 Dec;35 Suppl:S129-S150. doi: 10.1016/j.semcancer.2015.10.002. Epub 2015 Oct 8. Review.

6.

The cytotoxicity of 3-bromopyruvate in breast cancer cells depends on extracellular pH.

Azevedo-Silva J, Queirós O, Ribeiro A, Baltazar F, Young KH, Pedersen PL, Preto A, Casal M.

Biochem J. 2015 Apr 15;467(2):247-58. doi: 10.1042/BJ20140921.

PMID:
25641640
7.

Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy.

Majkowska-Skrobek G, Augustyniak D, Lis P, Bartkowiak A, Gonchar M, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Anticancer Drugs. 2014 Jul;25(6):673-82. doi: 10.1097/CAD.0000000000000094.

PMID:
24557015
8.

3-Bromopyruvate: a novel antifungal agent against the human pathogen Cryptococcus neoformans.

Dyląg M, Lis P, Niedźwiecka K, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Biochem Biophys Res Commun. 2013 May 3;434(2):322-7. doi: 10.1016/j.bbrc.2013.02.125. Epub 2013 Mar 26.

PMID:
23541578
9.

Human Hepatocellular Carcinoma Metabolism: Imaging by Hyperpolarized 13C Magnetic Resonance Spectroscopy.

Darpolor MM, Kaplan DE, Pedersen PL, Glickson JD.

J Liver Disease Transplant. 2012 Sep 1;1(1). doi: 10.4172/2325-9612.1000101.

10.

Mitochondria in relation to cancer metastasis: introduction to a mini-review series.

Pedersen PL.

J Bioenerg Biomembr. 2012 Dec;44(6):615-7. doi: 10.1007/s10863-012-9470-z.

PMID:
22926290
12.

Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae.

Lis P, Zarzycki M, Ko YH, Casal M, Pedersen PL, Goffeau A, Ułaszewski S.

J Bioenerg Biomembr. 2012 Feb;44(1):155-61. doi: 10.1007/s10863-012-9421-8. Epub 2012 Feb 23.

PMID:
22359102
13.

Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate.

Queirós O, Preto A, Pacheco A, Pinheiro C, Azevedo-Silva J, Moreira R, Pedro M, Ko YH, Pedersen PL, Baltazar F, Casal M.

J Bioenerg Biomembr. 2012 Feb;44(1):141-53. doi: 10.1007/s10863-012-9418-3. Epub 2012 Feb 17.

PMID:
22350013
14.

Mitochondrial ATP synthase catalytic mechanism: a novel visual comparative structural approach emphasizes pivotal roles for Mg²⁺ and P-loop residues in making ATP.

Blum DJ, Ko YH, Pedersen PL.

Biochemistry. 2012 Feb 21;51(7):1532-46. doi: 10.1021/bi201595v. Epub 2012 Feb 9.

PMID:
22243519
15.

Bcl-xL regulates mitochondrial energetics by stabilizing the inner membrane potential.

Chen YB, Aon MA, Hsu YT, Soane L, Teng X, McCaffery JM, Cheng WC, Qi B, Li H, Alavian KN, Dayhoff-Brannigan M, Zou S, Pineda FJ, O'Rourke B, Ko YH, Pedersen PL, Kaczmarek LK, Jonas EA, Hardwick JM.

J Cell Biol. 2011 Oct 17;195(2):263-76. doi: 10.1083/jcb.201108059. Epub 2011 Oct 10.

16.

Voltage dependent anion channel-1 (VDAC-1) as an anti-cancer target.

Mathupala SP, Pedersen PL.

Cancer Biol Ther. 2010 Jun 15;9(12):1053-6. Epub 2010 Jun 21. No abstract available.

17.

The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies.

Mathupala SP, Ko YH, Pedersen PL.

Biochim Biophys Acta. 2010 Jun-Jul;1797(6-7):1225-30. doi: 10.1016/j.bbabio.2010.03.025. Epub 2010 Apr 8. Review.

18.

Mitochondrial matters of the brain: amyloid formation and Alzheimer's disease introduction.

Pedersen PL.

J Bioenerg Biomembr. 2009 Oct;41(5):403-5. doi: 10.1007/s10863-009-9248-0.

PMID:
19882355
19.

Mitochondrial matters of the heart: a plethora of regulatory modes to maintain function for a long lifetime.

Pedersen PL.

J Bioenerg Biomembr. 2009 Apr;41(2):95-8. doi: 10.1007/s10863-009-9219-5. Review.

PMID:
19513821
20.

Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.

Mathupala SP, Ko YH, Pedersen PL.

Semin Cancer Biol. 2009 Feb;19(1):17-24. doi: 10.1016/j.semcancer.2008.11.006. Epub 2008 Dec 3. Review.

Supplemental Content

Loading ...
Support Center